BRCA1 and breast carcinoma: Accumulating evidence suggests that further clinical exploration of PARPi as monotherapy or combinations have shown benefit in patients with BRCA1 or BRCA2 mutation (gBRCAm)-associated breast cancer, as well as in breast cancer with homologous recombination repair (HRR) dysfunction [80].